iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
  FDA PDUFA, expected approval for Sof/velpatasvir is this June 28 2016
High Efficacy of Sofosbuvir/Velpatasvir In HCV Genotypes 1-6 Infected Patients With Cirrhosis: Pooled Data From the ASTRAL 1, 2 and 3 Trials (12/14/15)
EASL: Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (04/18/16)
Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies - (12/08/15)
EASL: Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination - (04/21/16)
  iconpaperstack View Older Articles   Back to Top   www.natap.org